Pipeline

Pipeline Planning Phase 1 Phase 2 Phase 3
PISCES / KEYNOTE-695
OMS-102
  • TAVO + pembrolizumab in melanoma patients with immunologically cold tumors
OMS-104
  • TAVO + anti-PD-1 in neoadjuvant resectable melanoma
OMS-131
  • TAVO + anti-PD-1 + checkpoint inhibitor in R/R squamous cell carcinoma of the head and neck (SCCHN)
OMS-140
  • TAVO in triple negative breast cancer (TNBC)
OMS-141 / KEYNOTE-890
Underway
Completed/Ongoing
Planned

Learn more about our current clinical trials. Learn more